Lenalidomide

CHEMBL848 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
259.3 g/mol
LogP
-0.5
Phase
4

An immunomodulatory drug used to treat multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and certain leukemias. It stimulates immune cells to attack cancer, blocks new blood vessel formation in tumors, and has direct anti-tumor effects.

Peso Molecular

259,2600 g/mol

LogP

-0,50

TPSA

92,50 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O

InChI

InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

Molecular Formula

C13H13N3O3

HBD / HBA

2 / 4

Ligações Rotacionáveis

1

Átomos Pesados

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An immunomodulatory drug used to treat multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and certain leukemias. It stimulates immune cells to attack cancer, blocks new blood vessel formation in tumors, and has direct anti-tumor effects.

Yes, Lenalidomide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL848. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 216326. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.